Daraxonrasib, an investigational oral inhibitor targeting the KRAS gene mutation, is being used in expanded access programs at Nebraska Medicine for patients with stage IV pancreatic ductal adenocarcinoma and has shown promising results, including substantially longer survival compared with chemotherapy. Nebraskan doctors report that patients treated with daraxonrasib lived roughly twice as long as those on standard chemotherapy, and the drug can be taken at home as a daily pill. Former Nebraska Sen. Ben Sasse has publicly discussed his own pancreatic cancer diagnosis and his experience with the drug, which has helped raise awareness and demand for access. The drug has not yet FDA-approved in the United States, but Revolution Medicines announced that its NDA for daraxonrasib in metastatic pancreatic cancer has been accepted for review, supported by positive phase 3 trial data showing significant improvements in overall survival and progression-free survival. Regulators have also noted strong responses in patients with the G12 mutation, and the company is pursuing regulatory reviews in Europe as well. The overall picture is one of a potentially practice-changing therapy under careful regulatory scrutiny that is already reaching patients through expanded access channels while formal approvals proceed.